Market Intelligence, Clinical Progress, and High-Purity Reagents for Prostate Cancer and Developmental Biology Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NKX3-1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NKX3-1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 or E. coli expressed. |
View NKX3-1 Products |
| Gene Delivery | NKX3-1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View NKX3-1 Products |
| Benchmark Ab | Anti-NKX3-1 Antibody Recombinant positive control for IHC, Western Blot, and ChIP. |
View NKX3-1 Products |
| Validator | NKX3-1 siRNA Set For knockdown verification in functional assays. |
View NKX3-1 Products |
| Related Target A | AR (Androgen Receptor) Primary upstream regulator of NKX3-1 expression in prostate tissue. |
View AR Products |
| Related Target B | PTEN Co-deleted or co-mutated with NKX3-1 in aggressive prostate cancer models. |
View PTEN Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Nuclear localization & transcription factor folding | HEK293 Expressed full-length protein preserving native post-translational modifications |
| Diagnostic specificity screening (HOX family off-targets) | Homolog panel screening utilizing sequence-verified recombinant proteins |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live NKX3-1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NKX3-1 therapeutics is intensifying, with major players shifting focus from traditional diagnostics to innovative target-reactivation strategies, gene therapies, and immunotherapy. As first-generation therapies reach the clinic, the next wave of R&D is targeting the restoration of NKX3-1 suppression pathways and targeting NKX3-1-derived peptides for TCR-T cell therapies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Diagnostic IHC / CDx | Roche/Ventana, Agilent/Dako | Prostate Adenocarcinoma | Specificity Validation (Need sequence-verified recombinant protein) |
| TCR-T / Cancer Vaccine | Academic Institutes, Biotech | Metastatic CRPC | HLA-peptide binding & T-cell activation (Need high-purity protein/peptides) |
| Gene Therapy / mRNA | Preclinical Biotechs | Advanced Prostate Cancer | Overexpression verification (Need Lentivirus and validated siRNA) |